Clinical Trial Update: Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry

View source ↗

Summary

A pregnancy registry trial evaluating miltefosine (Impavido) for leishmaniasis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leishmaniasis

Drugs mentioned

• Impavido (miltefosine)

Snippet

Sponsor: Knight Therapeutics (USA) Inc | Conditions: Leishmaniasis or Other Uses of Miltefosine | Status: WITHDRAWN